MKI67 and breast cancer: Since the concordance between the HG and Ki67 rate was high for HG1 and HG3 tumors and since the prognostic value regarding distant relapse of Ki67 rate was significant in the ER+ HER2− HG2 subgroup, we concluded that the Ki67 rate is a potential cost-effective prognostic proliferation marker in this later subgroup which represents 37% of early stage pN0 breast cancer patients.